🔎 Trials Near Me

Home › Kanser sa Traktong Biliary › Kentucky

Pag-aaral pangklinika para sa Kanser sa Traktong Biliary sa Kentucky

6 pag-aaral para sa Kanser sa Traktong Biliary ang naghahanap ng mga kalahok sa mga site sa Kentucky.

Mga Lungsod sa Kentucky

Opisyal na teksto ng pag-aaral (English)

AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2

  • Research Site, Louisville
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 30, 2026 · NCT06219941

A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer

  • Norton Cancer Institute (Site 115), Louisville
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07265674

Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)

  • Norton Cancer Institute, Louisville
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT05482893

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

  • Research Site, Louisville
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 28, 2026 · NCT07221253

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

  • Norton Cancer Institute - Audubon, Louisville
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT06282575

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

  • St. Elizabeth Healthcare, Edgewood
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 21, 2026 · NCT06774963

Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.